Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07836803

TORCH-LATAM-002: Regional Pathway for Adult Heart Transplant Evaluation and Candidacy

TORCH-LATAM-002 is a pragmatic stepped-wedge cluster randomized trial evaluating an integrated regional pathway for adults with advanced heart failure who require specialized heart transplant evaluation and a documented candidacy decision. Participating network clusters transition from usual local pathways to the TORCH Adult Heart Transplant Evaluation and Candidacy Pathway. The primary outcome is completion of multidisciplinary evaluation and a documented transplant-candidacy decision within 90 days after enrollment. The study also examines pathway activation, barriers, clinical outcomes, waiting-list trajectories, and traceable donor-organ opportunities. Enrollment does not constitute placement on an official waiting list, organ allocation, or authorization of cross-border care.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Each TORCH regional network cluster is anchored in an authorized transplant center and may include activated evaluation, referral, identification, donor-origin, procurement, preservation, logistics, and data-coordination nodes. Adults may be identified at transplanting or non-transplanting centers when an authorized route to specialized evaluation exists. The transplant center and competent authorities retain all legal and clinical authority for candidacy, waiting-list activation, organ acceptance, allocation, and transplantation.

The recipient pathway records identification, referral, enrollment, completion of multidisciplinary evaluation, documented candidacy decision, barrier management, activation of an authorized pathway or official waiting list, clinical change while waiting, donor-recipient opportunity, transplantation, or an alternative outcome. Study enrollment is analytically distinct from transplant candidacy and official wait-list status.

The donor-organ pathway records identification of a possible donor, confirmation of the applicable donation pathway, authorization, organ characterization, activation of an evaluable donor-organ opportunity, compatibility assessment, organ acceptance or rejection, procurement, preservation, transport, implantation, and final disposition. Donation after brain death and donation after circulatory determination of death are represented as distinct branches; normothermic regional perfusion is recorded only when applicable.

The two pathways converge at a traceable donor-organ-recipient matching episode. A characterized organ may be assessed for more than one compatible recipient, and each offer, decision, reason for non-acceptance, reassignment, urgency change, distance, logistics constraint, and final disposition is time-stamped. TORCH does not create a supranational allocation authority and does not override governmental or institutional systems.

Interoperability may range from audited manual transfer to structured documents, batch exchange, application programming interfaces, standards-based exchange, or validated remote-monitoring devices. Lack of an automated interface does not by itself exclude a site or participant when an authorized, secure, timely, and auditable fallback is available. Cross-border activity is activated only after applicable ethical, regulatory, institutional, data-protection, financial, and operational approvals.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years or older.
  • Advanced heart failure or acquired or structural heart disease meeting a protocol-defined trigger for specialized heart transplant evaluation.
  • Identification within an activated TORCH network cluster with an operational route to at least one authorized transplant center.
  • Ability to complete the protocol-defined follow-up directly or through an authorized network pathway.
  • Provision of informed consent according to applicable requirements.

Exclusion criteria

  • Primary congenital heart disease managed under the pediatric or congenital TORCH protocol.
  • No authorized route for protocol evaluation or follow-up at the time of enrollment.
  • Unable or unwilling to provide informed consent when required.
  • The prespecified multidisciplinary evaluation and transplant-candidacy decision were already completed before the enrollment reference time.

Treatment and study plan

TORCH Adult Heart Transplant Evaluation and Candidacy Pathway

Other

A multicomponent health-services pathway that standardizes identification, referral, multidisciplinary evaluation, candidacy documentation, barrier navigation, longitudinal wait-list status, donor-organ opportunity traceability, and authorized information exchange across activated network nodes. The pathway supports but does not replace institutional or governmental clinical, listing, allocation, or regulatory decisions.

Primary outcomes

  1. Completion of Multidisciplinary Advanced Heart Failure Evaluation and Documented Transplant Candidacy Decision Within 90 Days

    Time frame: Within 90 days after enrollment.

    Percentage of eligible enrolled participants who complete the prespecified multidisciplinary advanced heart failure evaluation and have a documented transplant-candidacy decision within 90 days after enrollment. A completed decision includes candidate for pathway or wait-list activation, conditional candidate with modifiable risk, not a candidate for isolated heart transplantation, too stable or transplant not currently indicated, or an alternative therapeutic pathway. An incomplete evaluation is not counted as success.

Secondary outcomes

  1. Activation of an Authorized Pathway or Official Waiting List

    Time frame: Within 180 days after the first documented transplant-candidacy decision qualifying for pathway or waitlist activation.

    Percentage of participants with a candidacy decision qualifying for activation who achieve documented activation of an authorized treatment pathway or official waiting list. Enrollment and candidacy do not themselves constitute listing.

  2. Time to Completed Evaluation and Candidacy Decision

    Time frame: From enrollment to completed evaluation and documented candidacy decision, assessed through 180 days.

    Time from enrollment to completion of the prespecified multidisciplinary evaluation and documentation of a transplant-candidacy decision.

  3. Participant-Level Barriers to Evaluation and Pathway Activation

    Time frame: Through 90 days after enrollment.

    Number and percentage of participants with prespecified clinical, administrative, financial, regulatory, logistical, geographic, social, technological, or data-exchange barriers. Multiple categories may be recorded.

  4. Resolution of Identified Barriers

    Time frame: Within 180 days after identification of each barrier.

    Percentage of prespecified barriers documented as resolved, with resolution defined by the barrier-specific rule.

  5. Heart Transplantation

    Time frame: Through 24 months after enrollment.

    Percentage of enrolled participants who undergo heart transplantation.

  6. Death or Irreversible Clinical Deterioration

    Time frame: Through 24 months after enrollment.

    Percentage of enrolled participants who die or develop protocol-defined irreversible deterioration that precludes the intended transplant pathway.

  7. Durable Mechanical Circulatory Support Implantation

    Time frame: 24 months after enrollment.

    Percentage of enrolled participants receiving durable mechanical circulatory support. Temporary extracorporeal membrane oxygenation or other temporary support is not counted.

  8. Utilization of TORCH-Evaluated Donor Organs

    Time frame: Perioperative/periprocedural period; at final disposition of each donor organ.

    Percentage of donor organs meeting the prespecified TORCH donor-organ opportunity denominator that are implanted. Final disposition is classified as implanted, recovered but not implanted, or not recovered. Prespecified reasons for non-use are recorded.

Study contacts

Contact information is provided by the study sponsor or research team.

Eliecer Villamizar De La Hoz, MD

CONTACT

[email protected]

+50370876226

Sponsors and collaborators

Lead sponsor

CardioVision International Tech, S.A.S. de C.V.

Industry

Collaborators

  • Advanced Science Technologies S.A.S.
  • Advanced Sciences Technologies, S.A. de C.V.

Registry information

Official study title

A Stepped-Wedge Cluster Randomized Trial of the TORCH Adult Heart Transplant Evaluation and Candidacy Pathway for Adults With Advanced Heart Failure in Latin America

Acronym: TORCH-002

Important dates

Study start
2027
Primary completion
2029
Study completion
2031
First posted
Sep 23, 2026
Registry last updated
Sep 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.